EP3322731

BRISTOL-MYERS SQUIBB COMPANY
Application Number
EP16744626A
Filing Date
Jul 14, 2016
Status
Granted And Under Opposition
Dec 11, 2020
Grant Date
Jan 13, 2021
External Links
Slate, Register

Biblio Summary

The patent EP3322731B1 was granted on Jan 13, 2021 by Bristol-Myers Squibb Company The patent is currently Granted And Under Opposition.

The table below shows 9 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

APPLEYARD LEES IP LLP / FLECK BARBARAOct 13, 2021ADMISSIBLE
GREINER, ELISABETHOct 13, 2021ADMISSIBLE
MAIWALD GMBHOct 13, 2021ADMISSIBLE
BIONTECH SEOct 12, 2021ADMISSIBLE
MERCK SHARP & DOHME LLCOct 12, 2021ADMISSIBLE
PATENT BOUTIQUE LLPOct 12, 2021ADMISSIBLE
KRAUS & LEDERER PARTGMBBOct 7, 2021ADMISSIBLE
REGENERON PHARMACEUTICALS, INC.Oct 7, 2021ADMISSIBLE
ISA PHARMACEUTICALS B.VOct 6, 2021ADMISSIBLE

The table below shows the patents of Bristol-Myers Squibb Company that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3631454Treatment Of Lag-3 Positive TumorsSep 13, 20232
EP3559230Methods For Increasing The Efficiency Of Homology Directed Repair (Hdr) In The Cellular GenomeSep 6, 20232
EP3227333Bispecific Antibodies Against Cd3Epsilon And Bcma For Use In Treatment Of DiseasesAug 16, 20233

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.